Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall Survival of Patients With ALK-Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study.
Tsimafeyeu I, Moiseenko F, Orlov S, Filippova E, Belonogov A, Nebesnykh A, Khalimov A, Karabina E, Shikina V, Abdelgafur A, Statsenko G, Titova I, Isaichikov D, Makarnyaeva G, Mordovskiy A, Barkovskaya O, Smirnov A, Gikalo M, Savelov N, Kosov D, Imyanitov E, Demidova I, Tjulandin S. Tsimafeyeu I, et al. Among authors: orlov s. J Glob Oncol. 2019 May;5:1-7. doi: 10.1200/JGO.19.00024. J Glob Oncol. 2019. PMID: 31095455 Free PMC article.
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
Planchard D, Reinmuth N, Orlov S, Fischer JR, Sugawara S, Mandziuk S, Marquez-Medina D, Novello S, Takeda Y, Soo R, Park K, McCleod M, Geater SL, Powell M, May R, Scheuring U, Stockman P, Kowalski D. Planchard D, et al. Among authors: orlov s. Ann Oncol. 2020 May;31(5):609-618. doi: 10.1016/j.annonc.2020.02.006. Epub 2020 Feb 20. Ann Oncol. 2020. PMID: 32201234 Free article. Clinical Trial.
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, Demirci U, Christopoulos P, Cicin I, Basal FB, Yilmaz C, Fedor M, Korkmaz T, Paydas S, Gautschi O, Zirtiloglu A, Eralp Y, Cinkir HY, Sezer A, Erman M, Tural D, Turna H, Mazieres J, Dudnik E, Reguart N, Camidge DR, Ng TL, Şenler FÇ, Beypınar İ, Yazılıtaş D, Demirkazık A, Karaoğlu A, Okutur K, Coşkun HŞ, Şendur MAN, Isikdogan A, Cabuk D, Yumuk PF, Yıldız I, Kaplan MA, Özyılkan Ö, Öztop İ, Olmez OF, Aydin K, Aydıner A, Meydan N, Grinberg RD, Roisman LC. Peled N, et al. Among authors: orlov s. Lung Cancer. 2020 Oct;148:48-54. doi: 10.1016/j.lungcan.2020.07.022. Epub 2020 Jul 27. Lung Cancer. 2020. PMID: 32799090
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.
Tan EH, Ramlau R, Pluzanska A, Kuo HP, Reck M, Milanowski J, Au JS, Felip E, Yang PC, Damyanov D, Orlov S, Akimov M, Delmar P, Essioux L, Hillenbach C, Klughammer B, McLoughlin P, Baselga J. Tan EH, et al. Among authors: orlov s. Ann Oncol. 2010 Feb;21(2):217-222. doi: 10.1093/annonc/mdp520. Ann Oncol. 2010. PMID: 20110292 Free PMC article. Clinical Trial.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE. Ramlau R, et al. Among authors: orlov sv. J Clin Oncol. 2008 Apr 10;26(11):1886-92. doi: 10.1200/JCO.2007.12.2614. J Clin Oncol. 2008. PMID: 18398154 Clinical Trial.
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M, Mellemgaard A, Novello S, Orlov S, Summers Y, von Pawel J, Stöhr J, Kaiser R, Reck M. Gottfried M, et al. Among authors: orlov s. Target Oncol. 2017 Aug;12(4):475-485. doi: 10.1007/s11523-017-0517-2. Target Oncol. 2017. PMID: 28702806 Clinical Trial.
Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.
Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM. Ponomarenko DM, et al. Oncotarget. 2017 Mar 25;8(32):53730-53739. doi: 10.18632/oncotarget.16574. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881846 Free PMC article.
615 results